38 results about "Severe fever with thrombocytopenia syndrome virus" patented technology

The invention relates to a severe fever with thrombocytopenia syndrome virus (SFTSV), an entire gene sequence represented by Hubei isolate HB29, amino acid sequences of coding proteins and application. The entire gene sequence of the virus is subjected to homology analysis. The virus belongs to bunyaviridae and comprises three gene segments, namely, L, M and S which represent polymerase and glycoprotein (Gn and Gc), nucleoprotein (NP) and non-structural proteins (NSs) of the virus respectively, and the three segments are all positioned on the branch of phlebovirus but farther from other viruses of phlebovirus. The entire gene sequence and the coding proteins of the virus can be used for developing drugs, vaccines or diagnostic reagents for preventing and treating the epidemic diseases caused by the SFTSV.

The invention belongs to the technical field of biological medicines, and relates to a codon optimized severe fever with thrombocytopenia syndrome virus (SFTSV) glycoprotein Gn gene sequence carrying tPA signal peptide and a nucleic acid vaccine thereof. The SFTSV glycoprotein Gn nucleic acid vaccine is composed of the codon optimized SFTSV glycoprotein Gn gene sequence and a eukaryotic expression vector pJW4303, and the 5'end of the SFTSV glycoprotein Gn gene sequence is connected with a tPA signal peptide sequence. Compared with a nucleic acid vaccine in a wild type state, the nucleic acid vaccine can express objective protein more efficiently and can effectively secrete the objective protein out of cells in gene expression, and an immune system can be effectively stimulated to produce good humoral immune response after a mammal is inoculated with the nucleic acid vaccine.

The invention belongs to the technical field of biology and particularly relates to a reverse transcription-recombinase polymerase amplification (RT-RPA) detecting kit for severe fever with thrombocytopenia syndrome viruses (SFTSV) and a preparation method of the detecting kit. The detecting kit is composed of an RT-RPA reaction system, an RNA enzyme inhibitor, an SFTS virus fragment L positive plasmid Puc-L, a negative quality control, a fragment L RPA primer and an exo probe. A rapid, sensitive and specific isothermal real-time fluorescent nucleic acid detection method for SFTSV is established by using the specific primer and the probe through real-time fluorescent detection realized by preparing the RT-RPA reaction system and placing a Twista real-time fluorescent detection instrument to carry out real-time fluorescent detection. The invention relates to application of the specific RPA primer and the exo probe to clinical differential diagnosis of SFTSV infection and identification of a virus isolate strain.

The invention relates to detection kits in the technical field of biology, in particular to a polypeptide-ELISA (enzyme-linked immunosorbent assay) kit for detecting a specific antibody of an N (nucleocapsid) protein of an SFTSV (severe fever with thrombocytopenia syndrome virus). The kit comprises an ELISA plate pre-coated with synthetic SFTSV N protein linear B-cell antigenic polypeptide, a sample diluent, negative control serum, positive control serum, an HRP (horse radish peroxidase) marked antibody, a concentrated cleaning solution, an enzyme substrate solution and a stop buffer. The kit has the advantages of high specificity, good repeatability and simplicity, convenience and rapidness in operation, and can be widely used for evaluating SFTSV infection conditions.

The invention belongs to the technical field of biomedicine and relates to codon-optimized severe fever with thrombocytopenia syndrome virus nucleoprotein gene and nucleic acid vaccine thereof. The codon-optimized gene sequence takes into account the codon usage preference of mammalian cells, and the sequence is shown in SEQ ID NO.2. The involved severe fever with thrombocytopenia syndrome virus nucleoprotein nucleic acid vaccine is composed of codon-optimized severe fever with thrombocytopenia syndrome virus nucleoprotein gene sequence and eukaryotic expression vector pJW4303, whose 5' end is connected with tPA signal peptide sequence. The nucleic acid vaccine effectively stimulates the immune system after immunizing the mammal, and produces a better humoral immune response.

The present invention relates to an antibody which specifically binds to the envelope glycoprotein of severe fever with thrombocytopenia syndrome virus (SFTSV), the pathogen of severe fever with thrombocytopenia syndrome (SFTS), and is used in order to effectively detect or diagnosis SFTSV and treat SFTS.

The invention relates to an SFTSV (severe fever with thrombocytopenia syndrome virus) combinable polypeptide which comprises three complementary determining regions CDR1-3, wherein the sequence of CDR1 is or comprises sequences shown in SEQ ID NO:1 in the description; the sequence of CDR2 is or comprises sequences shown in SEQ ID NO:2 in the description; and the sequence of CDR3 is or comprises one of sequences shown in SEQ ID NO:3 in the description. The invention aims to SFTS (severe fever with thrombocytopenia syndrome) which has a high fatality rate but the lack of effective vaccines or specific antiviral drugs and implements nano antibody drug development and research and development of diagnostic kits, through preparation of GN (glycoprotein N) protein, immune bactrian camels, a platform technology of displaying nano monoclonal antibodies through a phage library, and the like, a nano antibody VHH (variable heavy chain domain) which is specifically combined with GN is screened, CDR (complementary determining region) sequences of the nano antibody are identified, and a humanized antibody SNB is established; and meanwhile, the treatment effect of the SNB in treating SFTSV infection is assessed by using a humanized mouse model in vivo. By adopting the polypeptide, a novel potential nano antibody drug is provided for clinical treatment on SFTS, and meanwhile, a corresponding detection kit is provided for diagnosis on SFTS.

The invention relates to a reagent kit and application thereof, particularly relates to an isothermal amplification reagent kit for detecting fever and thrombocytopenia syndrome viruses and application of the isothermal amplification reagent kit, and belongs to the field of biotechnologies. The isothermal amplification reagent kit for detecting the fever and thrombocytopenia syndrome viruses contains oligonucleotide and comprises RNA (ribonucleic acid) extraction reagents (1), isothermal amplification reaction liquid (2), positive control templates (3) and negative control components (4). The isothermal amplification reaction liquid (1) comprises 1*Bst Buffer, betaine, MgSO<4>, dNTPs, RNase inhibitors, Bst DNA (deoxyribonucleic acid) polymerase, AMV reverse transcriptase, sterile deionized water, upstream and downstream strand displacement primers, upstream and downstream probes and a cross amplification primer; the positive control templates (3) are in-vitro transcription products of M gene segments of the fever and thrombocytopenia syndrome viruses; the negative control components (4) are sterile deionized water. The isothermal amplification reagent kit and the application have the advantages that the isothermal amplification reagent kit is high in detection sensitivity, specificity and repeatability, simple in operation step and short in reaction time, and has a broad application prospect, integral reaction procedures can be carried out at the same temperatures, the fever and thrombocytopenia syndrome viruses can be detected only by the aid of a single isothermal instrument, and the like.

The invention relates to a severe fever with thrombocytopenia syndrome virus (SFTSV), an entire gene sequence represented by Hubei isolate HB29, amino acid sequences of coding proteins and application. The entire gene sequence of the virus is subjected to homology analysis. The virus belongs to bunyaviridae and comprises three gene segments, namely, L, M and S which represent polymerase and glycoprotein (Gn and Gc), nucleoprotein (NP) and non-structural proteins (NSs) of the virus respectively, and the three segments are all positioned on the branch of phlebovirus but farther from other viruses of phlebovirus. The entire gene sequence and the coding proteins of the virus can be used for developing drugs, vaccines or diagnostic reagents for preventing and treating the epidemic diseases caused by the SFTSV.

The invention discloses a severe fever with thrombocytopenia syndrome virus (SFTSV) inhibitor. The SFTSV inhibitor is a monoclonal antibody against SFTSV, wherein variable structural domain of heavy chain of the SFTSV inhibitor contains the sequence of CDR-H1 given in SEQ ID NO:1, the sequence of CDR-H2 given in SEQ ID NO:2 and the sequence of CDR-H3 given in SEQ ID NO:3; and moreover, variable structural domain of light chain of the SFTSV inhibitor contains the sequence of CDR-L1 given in SEQ ID NO:4, the sequence of CDR-L2 given in SEQ ID NO:5 and the sequence of CDR-L3 given in SEQ ID NO:6.The invention further extends to therapeutic use of the SFTSV inhibitor, compositions thereof, and a method for detecting SFTSV thereby.

The invention discloses the application of compound PS-341 in the preparation of Bunyaviridae phlebovirus inhibitors, said compound PS-341 has a structure shown in formula (I): experiments have proved that compound PS-341 can inhibit Bunyaviridae Fever with thrombocytopenia syndrome virus, Ukuku virus, or Sicilian sandfly fever virus in the subviridae Phlebovirus genus. PS‑341 can inhibit the degradation of RIG‑I ubiquitination pathway mediated by SFTSV NSs, so that host cells can activate the interferon antiviral pathway during virus infection, and significantly inhibit virus replication and proliferation.

The invention relates to a human monoclonal antibody specifically combined with envelope protein Gn of severe fever with thrombocytopenia syndrome virus and application of the human monoclonal antibody. The antibody can specifically treat infection of severe fever with thrombocytopenia syndrome virus.

The invention discloses an application of a compound MLN4924 in preparation of a bunyaviridae phlebovirus virus inhibitor. The compound MLN4924 has a structure shown in the formula (I) (shown in the specification), and experiments prove that the compound MLN4924 can inhibit severe fever with thrombocytopenia syndrome viruses or Sicilian phlebotomus fever viruses in bunyaviridae phlebovirus viruses. According to the invention, ubiquitination degradation of RIG-I mediated by SFTSV NSs is inhibited, so that a host cell activates an interferon antiviral pathway during virus infection, and replication and proliferation of viruses are obviously inhibited.

The invention discloses application of rs1800818 to detection of severe fever with thrombocytopenia syndrome (FTLS) caused by severe fever with thrombocytopenia syndrome virus (FTLSV). The technical scheme to be protected is about application of substances for detecting the polymorphism or the genotype of rs1800818 in a personal genome to preparation of a product for screening FTLS and application of substances for detecting the polymorphism or the genotype of rs1800818 in a personal genome to preparation of a product for forecasting the condition of an FTLS patient. The substances for detecting the polymorphism or the genotype of rs1800818 can be combined with other substances (such as a substance for detecting other single nucleotide polymorphism or genotype related to FTLS) to prepare a product for screening FTLS patients or forecasting the conditions of FTLS patients.

The invention relates to preparation and application of an enzyme-linked immunosorbent assay (ELISA) kit for detecting novel bunyavirus antigen of feverwith thrombocytopenia associated syndrome. According to the kit, a domestic rabbit and a mouse are immunized by using severe febrile and thrombocytopenicyndrome virus, called novel bunyavirus JS-2007-001 for short, to obtain antiserum. An enzyme-linked reaction plate is coated by using rabbit antibody, mouse antibody is coupled with horse radish peroxidase (HRP), and auxiliary reagents such as an antigen quantitative reference and an enzyme substrate TMB (Tetramethylbenzidine) color developing agent are matched to form the kit.